tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Lineage Cell Therapeutics Inc

LCTX
Add to Watchlist
1.080USD
-0.020-1.80%
Close 07-31 16:00（ET）Quotes delayed by 15 min
269.24MMarket Cap
LossP/E TTM

Lineage Cell Therapeutics Inc

1.080
-0.020-1.80%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

LCTX Financials

See Lineage Cell Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Lineage Cell Therapeutics Inc Earnings Date

Latest Release
Aug 6, 2026
EPS / Forecast
--/-0.03
Revenue / Forecast
--/1.53M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
14.56M
53.24%
EPS(YoY)
-0.28
-197.00%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
-7.26%-0.02
126.34%0.00
-709.77%-0.13
-337.27%-0.13
48.81%-0.02
50.04%-0.01
60.48%-0.02
0.46%-0.03
-39.18%-0.04
27.02%-0.03
---0.04
---0.03
---0.03
---0.04
---0.12
----
----
----
----
----
Revenue
14.85%1.73M
130.40%6.61M
-2.59%3.68M
96.38%2.77M
4.02%1.50M
37.36%2.87M
203.29%3.78M
-56.34%1.41M
-39.48%1.44M
9.03%2.09M
-58.44%1.25M
-29.17%3.23M
-54.44%2.39M
63.96%1.92M
32.07%3.00M
789.26%4.55M
1239.39%5.24M
229.01%1.17M
297.55%2.27M
32.64%512.00K
Net Profit
-16.26%-4.81M
126.00%851.00K
-881.58%-29.78M
-428.89%-30.46M
36.73%-4.14M
31.46%-3.27M
57.33%-3.03M
-10.15%-5.76M
-49.63%-6.54M
24.85%-4.78M
-17.15%-7.11M
22.68%-5.23M
38.31%-4.37M
78.08%-6.35M
22.42%-6.07M
-41.25%-6.76M
-400.49%-7.09M
-1526.67%-28.99M
-0.81%-7.82M
26.59%-4.79M
Net Margin
-0.65%-277.62%
111.91%13.50%
-917.80%-808.26%
-167.83%-1098.16%
39.26%-275.83%
49.81%-113.32%
86.18%-79.41%
-154.14%-410.01%
-146.05%-454.16%
32.04%-225.77%
---574.48%
---161.33%
---184.58%
---332.22%
---156.33%
----
----
----
----
----
Gross Margin
2.46%100.00%
4.62%99.00%
0.88%99.86%
1.77%98.59%
4.71%97.60%
7.85%94.63%
14.53%98.99%
0.85%96.88%
-1.89%93.21%
-7.32%87.74%
--86.44%
--96.06%
--95.01%
--94.67%
--95.10%
----
----
----
----
----
Debt to assets ratio
-48.51%0.05%
-43.12%0.06%
-33.25%0.09%
-2.67%0.11%
-18.85%0.10%
-23.88%0.11%
-3.12%0.14%
-25.84%0.11%
-27.41%0.12%
45.88%0.14%
--0.14%
--0.15%
--0.16%
--0.10%
--0.03%
----
----
----
----
----
Income Statement
Revenue
14.85%1.73M
130.40%6.61M
-2.59%3.68M
96.38%2.77M
4.02%1.50M
37.36%2.87M
203.29%3.78M
-56.34%1.41M
-39.48%1.44M
9.03%2.09M
-58.44%1.25M
-29.17%3.23M
-54.44%2.39M
63.96%1.92M
32.07%3.00M
789.26%4.55M
1239.39%5.24M
229.01%1.17M
297.55%2.27M
32.64%512.00K
Operating profit
-16.73%-7.59M
-28.14%-6.55M
1.41%-3.79M
15.80%-4.94M
2.34%-6.50M
19.68%-5.11M
42.73%-3.84M
-16.78%-5.87M
-0.29%-6.66M
4.17%-6.36M
-27.69%-6.71M
-18.66%-5.02M
-3.85%-6.64M
76.49%-6.64M
23.26%-5.25M
40.20%-4.23M
9.28%-6.40M
-380.07%-28.24M
-1.75%-6.84M
-10.59%-7.08M
Net Profit
-16.26%-4.81M
126.00%851.00K
-881.58%-29.78M
-428.89%-30.46M
36.73%-4.14M
31.46%-3.27M
57.33%-3.03M
-10.15%-5.76M
-49.63%-6.54M
24.85%-4.78M
-17.15%-7.11M
22.68%-5.23M
38.31%-4.37M
78.08%-6.35M
22.42%-6.07M
-41.25%-6.76M
-400.49%-7.09M
-1526.67%-28.99M
-0.81%-7.82M
26.59%-4.79M
Balance Sheet
Current assets
12.36%56.16M
16.00%59.16M
22.85%42.26M
8.55%43.84M
9.34%49.98M
32.66%51.00M
-20.88%34.40M
-16.71%40.39M
-7.93%45.72M
-35.93%38.44M
-36.53%43.48M
-34.49%48.49M
-39.35%49.66M
-46.21%60.00M
0.24%68.51M
3.42%74.03M
26.69%81.87M
153.53%111.55M
72.00%68.34M
54.93%71.58M
Total current liabilities
-37.75%8.15M
-18.67%11.37M
-32.33%9.38M
-29.58%10.76M
-22.50%13.09M
-22.18%13.98M
-12.70%13.86M
-4.84%15.28M
-1.94%16.89M
-5.38%17.96M
-30.16%15.88M
-36.02%16.05M
-29.96%17.23M
-59.71%18.98M
158.66%22.74M
270.73%25.09M
271.44%24.59M
506.46%47.12M
13.42%8.79M
-9.99%6.77M
Total assets
-1.99%109.53M
-0.56%112.58M
-7.20%89.64M
-11.68%90.80M
3.01%111.75M
12.08%113.22M
-9.00%96.59M
-7.96%102.80M
-4.17%108.48M
-18.31%101.02M
-19.06%106.15M
-17.83%111.69M
-21.67%113.20M
-29.15%123.66M
-0.05%131.15M
0.87%135.92M
12.97%144.52M
61.69%174.54M
27.28%131.21M
20.23%134.75M
Total liabilities
66.69%56.84M
91.23%69.24M
116.49%68.84M
21.60%43.69M
-9.06%34.10M
-7.15%36.21M
-19.48%31.80M
-11.14%35.93M
-15.16%37.49M
-24.61%39.00M
-26.31%39.49M
-25.71%40.43M
-25.48%44.19M
-38.16%51.73M
361.11%53.59M
387.97%54.42M
422.12%59.30M
552.37%83.65M
-9.94%11.62M
-22.48%11.15M
Total equity
-32.14%52.70M
-43.72%43.35M
-67.90%20.80M
-29.55%47.11M
9.39%77.66M
24.17%77.01M
-2.80%64.79M
-6.15%66.88M
2.86%70.99M
-13.78%62.02M
-14.05%66.66M
-12.57%71.26M
-19.01%69.02M
-20.86%71.94M
-35.15%77.55M
-34.06%81.50M
-26.90%85.22M
-4.45%90.90M
32.61%119.59M
26.52%123.60M
Cash Flow Statement
Net operating income
-65.33%-8.08M
23.13%-4.88M
37.52%-3.62M
-7.01%-5.54M
15.51%-4.89M
-5.43%-6.35M
-14.89%-5.79M
17.42%-5.18M
48.56%-5.78M
27.51%-6.02M
8.08%-5.04M
11.24%-6.27M
-151.32%-11.24M
-41.38%-8.30M
-13.04%-5.48M
-30.39%-7.06M
395.04%21.90M
-4.11%-5.87M
-0.02%-4.85M
-27.77%-5.42M
Net investment
-222.23%-2.33M
-681.94%-15.33M
-100.31%-12.00K
99.84%-14.00K
5107.89%1.90M
-72.95%2.63M
83.22%3.89M
-145.89%-8.79M
-100.25%-38.00K
290.94%9.74M
105.19%2.12M
19851.55%19.16M
33634.78%15.43M
-3394.52%-5.10M
-60067.65%-40.91M
15.65%-97.00K
-100.46%-46.00K
-116.19%-146.00K
-138.20%-68.00K
-101.72%-115.00K
Net financing
10.25%5.56M
-6.23%20.38M
61233.33%1.83M
-392.38%-307.00K
-64.03%5.04M
167284.62%21.73M
-100.37%-3.00K
-98.13%105.00K
1402000.00%14.02M
-110.66%-13.00K
-16.29%807.00K
16954.55%5.63M
-99.81%1.00K
-87.21%122.00K
-74.08%964.00K
-99.71%33.00K
-97.55%513.00K
-80.18%954.00K
-84.86%3.72M
2145.33%11.29M

FAQs

What is the total revenue of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its total revenue reached 14.56M, with a year-on-year change of 9.50M.

What are the current assets of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its current assets were 59.16M, with a year-on-year change of 16.00.

What are the total assets of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its total assets of Lineage Cell Therapeutics Inc were 112.58M, with a year-on-year change of -0.56.

What are the total liabilities of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its total liabilities of Lineage Cell Therapeutics Inc were 69.24M, with a year-on-year change of 91.23.

What is the total equity of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its total equity of Lineage Cell Therapeutics Inc was 43.35M, with a year-on-year change of -43.72.

What is the net operating income of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its net operating income of Lineage Cell Therapeutics Inc was -21.78M, with a year-on-year change of -1.40.

What is the net investment of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its net investment of Lineage Cell Therapeutics Inc was -13.46M, with a year-on-year change of -483.06.

What is the net financing of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its net financing of Lineage Cell Therapeutics Inc was 26.95M, with a year-on-year change of -24.84.

What is the Earnings Per Share (EPS) of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -0.28, with a year-on-year change of -197.00.

What is the net income of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its net income was -63.53M, with a year-on-year change of -241.41.

What is the net margin of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its net profit margin was -435.33, with a year-on-year change of -122.54.

What is the gross margin of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its gross margin was 99.00, with a year-on-year change of 2.60.

What is the debt-to-asset ratio of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its debt-to-asset ratio was 0.06, with a year-on-year change of -43.12.

What is the Return on Equity (ROE) of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -103.36, with a year-on-year change of -293.82.

What is the Return on Assets (ROA) of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -56.13, with a year-on-year change of -223.55.

What is the operating profit of Lineage Cell Therapeutics Inc?

According to Lineage Cell Therapeutics Inc's FY2025 earnings report, its operating profit was -21.78M, with a year-on-year change of -1.40.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy